Arcutis Biotherapeutics, Inc.
NASDAQ: ARQT0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Todd Franklin Watanabe
- Employees
- 342
- Headquarters
- Westlake Village, United States
- IPO year
- 2020
- Market cap
- $3.4B
- Website
- https://www.arcutis.com
Loading ARQT…
Loading profile data…Frequently asked questions about ARQT
What does Arcutis Biotherapeutics, Inc. (ARQT) do?
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and ato...
Where does ARQT trade?
Arcutis Biotherapeutics, Inc. (ARQT) trades on the NASDAQ Global Select.
What sector is ARQT in?
Arcutis Biotherapeutics, Inc. (ARQT) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Arcutis Biotherapeutics, Inc.?
Todd Franklin Watanabe is the chief executive officer of Arcutis Biotherapeutics, Inc. (ARQT).
Where is Arcutis Biotherapeutics, Inc. headquartered?
Arcutis Biotherapeutics, Inc. is headquartered in United States.
Does ARQT pay a dividend?
Arcutis Biotherapeutics, Inc. (ARQT) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ARQT go public?
Arcutis Biotherapeutics, Inc. (ARQT) completed its initial public offering in 2020.